« Previous
Next »
Titles
- E11(R1) addendum: clinical investigation of medicinal products in the pediatric population1
- E14 and S7B clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential: questions and answers1
- E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)1
- E17 general principles for planning and design of multiregional clinical trials1
- E18 genomic sampling and management of genomic data1
- E19: a selective approach to safety data collection in specific late-stage preapproval or post-approval clinical trials : guidance for industry1
- E2B(R3) electronic transmission of Individual Case Safety Reports (ICSRs) implementation guide: data elements and message specification1
- E6(R2) good clinical practice: integrated addendum to ICH E6(R1)1
- E8(R1) general considerations for clinical studies1
- E9(R1) statistical principles for clinical trials: addendum : estimands and sensitivity analysis in clinical trials1
- Early challenges highlight areas for improvement in COVID-19 vaccination programs1
- Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines1
- Early learning and child care: agencies have helped address fragmentation and overlap through improved coordination : report to the Chairwoman, Committee on Education and the Workforce, House of Representatives1
- Early learning and child care: overview of federal investment and agency coordination : testimony before the Subcommittee on Early Childhood, Elementary, and Secondary Education, Committee on Education and the Workforce, House of Representatives1
- Economic effects of expanding home- and community-based services in Medicaid1
- Economic effects of five illustrative single-payer health care systems1
- Economic effects of offering a federal paid family and medical leave program1
- Effects of Medicare Advantage enrollment on beneficiary risk scores1
- Effects of the COVID-19 public health emergency on formal meetings and user fee applications for medical devices: questions and answers (revised) : guidance for industry and Food and Drug Administration staff1
- Effects of the Patient Protection and Affordable Care Act on coverage and access to care in metropolitan vs. non-metropolitan areas through 20161